Skip to main content Accessibility help
×
Home
Hostname: page-component-59b7f5684b-8dvf2 Total loading time: 6.444 Render date: 2022-09-28T20:51:02.682Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "displayNetworkTab": true, "displayNetworkMapGraph": false, "useSa": true } hasContentIssue true

Appendices

Published online by Cambridge University Press:  19 October 2021

Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr, 19, 432438.CrossRefGoogle ScholarPubMed
Meyer, J. M., Cummings, M. A., Proctor, G., et al. (2016). Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am, 39, 541556.CrossRefGoogle ScholarPubMed
Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Gilman: The Pharmacological Basis of Therapeutics (eds.). New York: McGraw-Hill.Google Scholar
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry, 81(3), 19cs13169.CrossRefGoogle ScholarPubMed

References

Castro, V. M., Roberson, A. M., McCoy, T. H., et al. (2016). Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study. Neuropsychopharmacol, 41, 11381143.CrossRefGoogle Scholar
Meyer, J. M. (2018). Gilman: The Pharmacological Basis of Therapeutics. Pharmacotherapy of Psychosis and Mania. New York: McGraw-Hill.Google Scholar

References

Beach, S. R., Celano, C. M., Noseworthy, P. A., et al. (2013). QTc prolongation, Torsades de Pointes, and psychotropic medications. Psychosomatics, 54, 113.CrossRefGoogle ScholarPubMed
Trinkley, K. E., Page, R. L., 2nd, Lien, H., et al. (2013). QT interval prolongation and the risk of Torsades de Pointes: essentials for clinicians. Curr Med Res Opin, 29, 17191726.CrossRefGoogle ScholarPubMed

References

Day, R. O., Snowden, L., McLachlan, A. J. (2017). Life-threatening drug interactions: what the physician needs to know. Intern Med J, 47, 501512.CrossRefGoogle Scholar
Voigt, N., Ort, K., Sossalla, S. (2019). Drug-drug interactions you should know!. Fortschr Neurol Psychiatr, 87, 320332.Google ScholarPubMed

References

Wald, A. (2015). Constipation: pathophysiology and management. Curr Opin Gastroenterol, 31, 4549.CrossRefGoogle ScholarPubMed
Prichard, D. O., Bharucha, A. E. (2018). Recent advances in understanding and managing chronic constipation. F1000Res, 7, 1640.CrossRefGoogle ScholarPubMed

References

Hofmann, W. P., Radle, J., Moench, C., et al. (2008). Prediction of perioperative mortality in patients with advanced liver disease and abdominal surgery by the use of different scoring systems and tests. Z Gastroenterol, 46, 12831289.CrossRefGoogle ScholarPubMed
Tsoris, A., Marlar, C. A. (2020). Use of the child Pugh score in liver disease. In StatPearls (eds.). Treasure Island, FL: StatPearls Publishing LLC.Google Scholar

References

Kook, K. A., Stimmel, G. L., Wilkins, J. N., et al. (1985). Accuracy and safety of a priori lithium loading. J Clin Psychiatry, 46, 4951.Google ScholarPubMed
Hirschfeld, R. M., Baker, J. D., Wozniak, P., et al. (2003). The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. J Clin Psychiatry, 64, 841846.CrossRefGoogle ScholarPubMed
Tohen, M., Ketter, T. A., Zarate, C. A., et al. (2003). Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry, 160, 12631271.CrossRefGoogle ScholarPubMed

References

Bakker, I. C., Schubart, C. D., Zelissen, P. M. (2016). Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole. Endocrinol Diabetes Metab Case Rep, 2016, 160028.Google ScholarPubMed
Grigg, J., Worsley, R., Thew, C., et al. (2017). Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl), 234, 32793297.CrossRefGoogle ScholarPubMed
Gonzalez-Rodriguez, A., Labad, J., Seeman, M. V. (2020). Antipsychotic-induced hyperprolactinemia in aging populations: prevalence, implications, prevention and management. Prog Neuropsychopharmacol Biol Psychiatry, 101, 109941.CrossRefGoogle ScholarPubMed

References

Marik, P. E., Varon, J. (2007). Hypertensive crises: challenges and management. Chest, 131, 19491962.CrossRefGoogle ScholarPubMed
Burton, T. J., Wilkinson, I. B. (2008). The dangers of immediate-release nifedipine in the emergency treatment of hypertension. J Hum Hypertens, 22, 301302.CrossRefGoogle ScholarPubMed
Yilmaz, S., Pekdemir, M., Tural, U., et al. (2011). Comparison of alprazolam versus captopril in high blood pressure: a randomized controlled trial. Blood Press, 20, 239243.CrossRefGoogle ScholarPubMed
Meyer, J. M. (2017). A concise guide to monoamine oxidase inhibitors: part 1. Current Psychiatry, 16, 1416.Google Scholar
Gillman, P. K. (2020). Monoamine oxidase inhibitors: a review concerning dietary tyramine and drug interactions. PsychoTropical Commentaries, PsychoTropical Research, Bucasia, Queensland, Australia. Available at: psychotropical.com/maois-diet-drug-interactions (last accessed November 13, 2020).Google Scholar

References

Gillman, P. K. (2003). Mirtazapine: unable to induce serotonin toxicity? Clin Neuropharmacol, 26, 288289; author reply 289–290.CrossRefGoogle ScholarPubMed
Gillman, P. K. (2006). A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Human Psychopharmacol, 21, 117125.CrossRefGoogle ScholarPubMed
Quante, A., Zeugmann, S. (2012). Tranylcypromine and bupropion combination therapy in treatment-resistant major depression: a report of 2 cases. J Clin Psychopharmacol, 32, 572574.CrossRefGoogle ScholarPubMed
Davis, R. E., Vanover, K. E., Zhou, Y., et al. (2015). ITI-007 demonstrates brain occupancy at serotonin 5-HT(2)A and dopamine D(2) receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology (Berl), 232, 28632872.CrossRefGoogle ScholarPubMed
Meyer, J. M. (2018). A concise guide to monoamine oxidase inhibitors: part 2. Current Psychiatry, 17, 2233.Google Scholar
Meyer, J. M. (2018). Gilman: The Pharmacological Basis of Therapeutics. Pharmacotherapy of Psychosis and Mania. New York: McGraw-Hill.Google Scholar
Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R., Knollmann, B. C. (eds.). Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th ed. Chicago, IL: McGraw-Hill, pp. 279302.Google Scholar

References

Smith, D., Smith, R., Misquitta, D. (2016). Neuroimaging and violence. Psychiatr Clin North Am, 39, 579597.CrossRefGoogle ScholarPubMed
Davidson, L. L., Heinrichs, R. W. (2003). Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res, 122, 6987.CrossRefGoogle ScholarPubMed
Hill, K., Mann, L., Laws, K. R., et al. (2004). Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand, 110, 243256.CrossRefGoogle ScholarPubMed
Sripada, C. S., Silk, K. R. (2007). The role of functional neuroimaging in exploring the overlap between borderline personality disorder and bipolar disorder. Curr Psychiatry Rep, 9, 4045.CrossRefGoogle ScholarPubMed
McDermott, B. E., Holoyda, B. J. (2014). Assessment of aggression in inpatient settings. CNS Spectr, 19, 425431.CrossRefGoogle ScholarPubMed
Poldrack, R. A., Monahan, J., Imrey, P. B., et al. (2018). Predicting violent behavior: what can neuroscience add? Trends Cogn Sci, 22, 111123.CrossRefGoogle ScholarPubMed
Stahl, S. M., Morrissette, D. A., Cummings, M., et al. (2014). California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectr, 19, 449465.CrossRefGoogle ScholarPubMed
Meyer, J. M., Cummings, M. A., Proctor, G., et al. (2016). Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am, 39, 541556.CrossRefGoogle ScholarPubMed
Morrissette, D. A., Stahl, S. M. (2014). Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr, 19, 439448.CrossRefGoogle ScholarPubMed
Cummings, M. A., Proctor, G. J., Arias, A. W. (2019). Dopamine antagonist antipsychotics in diverted forensic populations. CNS Spectr, in press, doi: 10.1017/S1092852919000841CrossRefGoogle Scholar
Citrome, L., Volavka, J. (2011). Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs, 25, 10091021.CrossRefGoogle ScholarPubMed
Correll, C. U., Yu, X., Xiang, Y., et al. (2017). Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting. Ann Clin Psychiatry, 29, 92107.Google ScholarPubMed
Levy, R. H., Friel, P. N., Johno, I., et al. (1984). Filtration for free drug level monitoring: carbamazepine and valproic acid. Ther Drug Monit, 6, 6776.CrossRefGoogle ScholarPubMed
Keck, P. E., Jr., McElroy, S. L., Bennett, J. A. (1996). Health-economic implications of the onset of action of antimanic agents. J Clin Psychiatry, 57 1318.Google ScholarPubMed
Leppik, I. E., Hovinga, C. A. (2013). Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations. Epilepsia, 54, 2835.CrossRefGoogle ScholarPubMed
Plenge, P., Stensgaard, A., Jensen, H. V., et al. (1994). 24-hour lithium concentration in human brain studied by Li-7 magnetic resonance spectroscopy. Biol Psychiatry, 36, 511516.CrossRefGoogle ScholarPubMed
Castro, V. M., Roberson, A. M., McCoy, T. H., et al. (2016). Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study. Neuropsychopharmacol, 41, 11381143.CrossRefGoogle Scholar
Malhi, G. S., Gessler, D., Outhred, T. (2017). The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord, 217, 266280.CrossRefGoogle ScholarPubMed
Chouinard, G. (2004). Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry, 65, 712.Google ScholarPubMed
Amodeo, G., Fagiolini, A., Sachs, G., et al. (2017). Older and newer strategies for the pharmacological management of agitation in patients with bipolar disorder or schizophrenia. CNS Neurol Disord Drug Targets, 16, 885890.Google ScholarPubMed
Liu, J., Chan, T. C. T., Chong, S. A., et al. (2019). Impact of emotion dysregulation and cognitive insight on psychotic and depressive symptoms during the early course of schizophrenia spectrum disorders. Early Interv Psychiatry, 14(6), 691697.CrossRefGoogle ScholarPubMed
Walsh, M. T., Dinan, T. G. (2001). Selective serotonin reuptake inhibitors and violence: a review of the available evidence. Acta Psychiatr Scand, 104, 8491.CrossRefGoogle ScholarPubMed
Beach, S. R., Kostis, W. J., Celano, C. M., et al. (2014). Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry, 75, e441449.CrossRefGoogle ScholarPubMed
Sanchez, C., Reines, E. H., Montgomery, S. A. (2014). A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol, 29, 185196.CrossRefGoogle ScholarPubMed
Chiu, C. C., Lane, H. Y., Huang, M. C., et al. (2004). Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol, 44, 13851390.CrossRefGoogle ScholarPubMed
Asnis, G. M., Thomas, M., Henderson, M. A. (2015). Pharmacotherapy treatment options for insomnia: a primer for clinicians. Int J Mol Sci, 17, 111.CrossRefGoogle ScholarPubMed
Ozdemir, P. G., Karadag, A. S., Selvi, Y., et al. (2014). Assessment of the effects of antihistamine drugs on mood, sleep quality, sleepiness, and dream anxiety. Int J Psychiatry Clin Pract, 18, 161168.CrossRefGoogle ScholarPubMed
Jang, D. H., Manini, A. F., Trueger, N. S., et al. (2010). Status epilepticus and wide-complex tachycardia secondary to diphenhydramine overdose. Clin Toxicol (Phila), 48, 945948.CrossRefGoogle ScholarPubMed
Tonda, M. E., Guthrie, S. K. (1994). Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy, 14, 543560.Google ScholarPubMed
Ogino, S., Miyamoto, S., Miyake, N., et al. (2014). Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci, 68, 3749.CrossRefGoogle ScholarPubMed
Praharaj, S. K., Kongasseri, S., Behere, R. V., et al. (2015). Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol, 5, 307313.CrossRefGoogle ScholarPubMed
Morkunas, B., Porritt, K., Stephenson, M. (2016). Experiences of mental health professionals and patients in the use of pro re nata medication in acute adult mental healthcare settings: a systematic review. JBI Database System Rev Implement Rep, 14, 209250.CrossRefGoogle ScholarPubMed
Maiocchi, L., Bernardi, E. (2013). Optimisation of prescription in patients with long-term treatment-resistant schizophrenia. Australas Psychiatry, 21, 446448.CrossRefGoogle ScholarPubMed
Remington, G., Addington, D., Honer, W., et al. (2017). Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry, 62, 604616.CrossRefGoogle ScholarPubMed
Patterson, T. L., Leeuwenkamp, O. R. (2008). Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr Res, 100, 108119.CrossRefGoogle ScholarPubMed
Deutschenbaur, L., Lambert, M., Walter, M., et al. (2014). Long-term treatment of schizophrenia spectrum disorders: focus on pharmacotherapy. Nervenarzt, 85, 363375.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Appendices
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Appendices
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Appendices
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×